Runben Biotechnology Co (SHSE:603193) EBIT: ¥402 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603193 Runben Biotechnology Co Ltd SHSE:603193
70 GF Score
Price ¥19.79
GF Value ¥28.89
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Runben Biotechnology Co EBIT?

Runben Biotechnology Co SHSE:603193 +1.07% 70 EBIT is ¥402 Mil as of Jun. 2026. GuruFocus rates SHSE:603193 with a GF Score™ of 70/100 and a GF Value™ of ¥28.89 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Runben Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was ¥202 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ¥402 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Runben Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2026 was 65.20%. Runben Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 145.34%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Runben Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.18%.


Runben Biotechnology Co  (SHSE:603193) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Runben Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=779.72116512 * ( 1 - 14.791% )/( (1163.1600515 + 874.89416297)/ 2 )
=664.3926075871/1019.027107235
=65.20 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2431.82095674 - 126.60188079 - ( 1142.05902445 - max(0, 154.38590817 - 1695.62334673+1142.05902445))
=1163.1600515

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2550.10320247 - 164.99431292 - ( 1510.21472658 - max(0, 205.45113169 - 1795.15550113+1510.21472658))
=874.89416297

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Runben Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=809.599837/( ( (300.53777492 + max(394.59942929, 0)) + (347.02012605 + max(71.94634501, 0)) )/ 2 )
=809.599837/( ( 695.13720421 + 418.96647106 )/ 2 )
=809.599837/557.051837635
=145.34 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(22.13238226 + 187.23082731 + 338.55735283) - (126.60188079 + 6.51190356 + 20.20734876)
=394.59942929

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(93.22373817 + 161.40787973 + 22.06100813) - (164.99431292 + 2.37323104 + 37.37873706)
=71.94634501

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Runben Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=401.758/6497.393
=6.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Runben Biotechnology Co EBIT Related Terms


Runben Biotechnology Co EBIT Historical Data

* Premium members only.

The historical data trend for Runben Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Runben Biotechnology Co EBIT Chart

Runben Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 142.22 189.51 268.28 352.24 362.41

Runben Biotechnology Co Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 169.77 93.44 48.70 57.22 202.40

SHSE:603193 vs PG, CL, EL: EBIT Comparison

For the Household & Personal Products subindustry, Runben Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Runben Biotechnology Co EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Runben Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Runben Biotechnology Co's EV-to-EBIT falls into.


SHSE:603193
70GF Score
Runben Biotechnology Co Ltd SHSE:603193
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Runben Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥402 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥402 Mil mean?
Runben Biotechnology Co (SHSE:603193) has a EBIT of ¥402 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Runben Biotechnology Co.
Is Runben Biotechnology Co's EBIT too high?
Runben Biotechnology Co's current EBIT is ¥402 Mil. Overall, Runben Biotechnology Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's EBIT compare to PG and CL?
Runben Biotechnology Co's EBIT of ¥402 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Runben Biotechnology Co. Runben Biotechnology Co's current EBIT is ¥402 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥28.89, compared to a current price of ¥19.79 — trading 31.5% below its estimated fair value. The current EBIT is ¥402 Mil. Runben Biotechnology Co's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current EBIT is ¥402 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?

Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued. The current stock price of ¥19.79 is trading 31.5% below its estimated GF Value™ of ¥28.89. GuruFocus considers Runben Biotechnology Co to be Significantly Undervalued.

Key valuation signals for SHSE:603193:

  • EBIT: ¥402 Mil
  • GF Value™: ¥28.89 vs. price of ¥19.79 (31.5% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Runben Biotechnology Co Business Description

Address No. 3, Xinzhuang 5th Road, Guangzhou Economic and Technological Development Zone, Guangdong, Guangzhou, CHN, 510627
Runben Biotechnology Co Ltd is engaged in research & development, production and sales of mosquito repellent and personal care products.
70GF Score

Get the complete analysis for SHSE:603193

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.79
Price
¥28.89
GF Value